London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
Lyn Rees, Chief Executive Officer of Yourgene Health, commented: "Our change of name to Yourgene Health marks the beginning of an exciting new period for the Group. It reflects our broadened capabilities within the genetic testing universe and the combining of the Premaitha and Yourgene Bioscience businesses.
"Within the NIPT segment, we are aggressively targeting further expansion through distribution and licensing partnerships. The consolidated Group is now well-placed to deliver services to a global market and maximise its revenue potential.
"Our technical expertise in genetic test development, partnerships with DNA technology majors and expanding global footprint also put us in a strong position to develop additional products both within reproductive health and oncology.
"I look forward to providing further updates on the commercialisation of the Group as we expand organically, through distribution and licensing agreements, and via third party partnerships."
Yourgene Health PLC Change of Name to Yourgene Health plc
07/11/2018 7:00am
UK Regulatory (RNS & others)
Premaitha (LSE:NIPT)
Intraday Stock Chart
Today : Wednesday 7 November 2018
TIDMYGEN
RNS Number : 5273G
Yourgene Health PLC
07 November 2018
Premaitha Health plc
("Premaitha" or the "Group")
Change of Name to Yourgene Health plc
&
Change of Website Address
Manchester, UK - 7 November 2018: Premaitha Health plc, the international molecular diagnostics group which commercialises genetic products and services that positively impact human health, is pleased to confirm the renaming of the Group as Yourgene Health plc ("Yourgene Health").
Further to the special resolution approved at the Group's Annual General Meeting on 25 October 2018, the Group's name has been changed to Yourgene Health plc and trading in the Group's shares under the new name and TIDM, "YGEN", will commence at 8.00 a.m. today. The Group's website is now available at www.yourgene-health.com.
The change of name reflects the Group's broadened product development and research service capabilities which extend across the lifecycle of DNA test development and commercialisation.
Yourgene Health's ongoing strategic priorities include:
-- developing and commercialising genetic products and services that positively impact human health;
-- driving worldwide sales of the Group's non-invasive prenatal testing ("NIPT") products and services by targeting further expansion through direct and key distribution channels to expand the geographic footprint;
-- continuing to offer highly customer-focused NIPT products and services which support all types of customer - irrespective of size, geography and market maturity - in partnership with leading DNA technology providers;
-- leveraging the Group's technical and regulatory expertise and partnerships to extend its genetic testing offering into complementary areas of reproductive health and oncology, both with owned intellectual property and as a third-party collaborator; and
-- supporting diagnostic majors and bioinformatics specialists with in vitro diagnostic product contract development partnerships.
Shareholdings will be unaffected by the change of name and existing share certificates should be retained as they will remain valid for all purposes. Any new share certificates issued will bear the name Yourgene Health plc.